PURPOSE: To evaluate spray-freeze drying and spray drying processes for fabricating micron-sized particles of darbepoetin alfa (NESP, Aranesp) with uniform size distribution and retention of protein integrity, requirements for encapsulation. METHODS: Darbepoetin alfa was spray-freeze dried using ultrasonic atomization at 120 kHz and 25 kHz and spray dried at bench-top and pilot scales. Reconstituted powders were evaluated by size exclusion chromatography and UV/VIS spectroscopy. Powder physical properties were also characterized. RESULTS: Spray-freeze drying resulted in aggregation of darbepoetin alfa. Aggregates (primarily insoluble) formed on drying and/or reconstitution. Particle size distributions were broad (span > or = 3.6) at both nozzle frequencies. Annealing before drying reduced aggregate levels slightly but increased particle size over 5-fold. Spray drying at inlet temperatures up to 135 degrees C (and outlet temperatures up to 95 degrees C) showed little impact on integrity. Integrity at bench-top and pilot scales was identical, with 0.2% dimer and no high molecular weight or insoluble aggregates detected. Particle size was small (< or = 2.3 microm) with uniform distribution (span < or = 1.4) at both process scales. CONCLUSIONS: Under the conditions tested spray drying, conducted at bench-top and pilot scales with commercially available equipment, was superior to spray-freeze drying for the fabrication of darbepoetin alfa particles for encapsulation.
PURPOSE: To evaluate spray-freeze drying and spray drying processes for fabricating micron-sized particles of darbepoetin alfa (NESP, Aranesp) with uniform size distribution and retention of protein integrity, requirements for encapsulation. METHODS: Darbepoetin alfa was spray-freeze dried using ultrasonic atomization at 120 kHz and 25 kHz and spray dried at bench-top and pilot scales. Reconstituted powders were evaluated by size exclusion chromatography and UV/VIS spectroscopy. Powder physical properties were also characterized. RESULTS: Spray-freeze drying resulted in aggregation of darbepoetin alfa. Aggregates (primarily insoluble) formed on drying and/or reconstitution. Particle size distributions were broad (span > or = 3.6) at both nozzle frequencies. Annealing before drying reduced aggregate levels slightly but increased particle size over 5-fold. Spray drying at inlet temperatures up to 135 degrees C (and outlet temperatures up to 95 degrees C) showed little impact on integrity. Integrity at bench-top and pilot scales was identical, with 0.2% dimer and no high molecular weight or insoluble aggregates detected. Particle size was small (< or = 2.3 microm) with uniform distribution (span < or = 1.4) at both process scales. CONCLUSIONS: Under the conditions tested spray drying, conducted at bench-top and pilot scales with commercially available equipment, was superior to spray-freeze drying for the fabrication of darbepoetin alfa particles for encapsulation.
Authors: J D Andya; Y F Maa; H R Costantino; P A Nguyen; N Dasovich; T D Sweeney; C C Hsu; S J Shire Journal: Pharm Res Date: 1999-03 Impact factor: 4.200
Authors: O L Johnson; J L Cleland; H J Lee; M Charnis; E Duenas; W Jaworowicz; D Shepard; A Shahzamani; A J Jones; S D Putney Journal: Nat Med Date: 1996-07 Impact factor: 53.440
Authors: Joshua D Engstrom; Edwina S Lai; Baltej S Ludher; Bo Chen; Thomas E Milner; Robert O Williams; G Barrie Kitto; Keith P Johnston Journal: Pharm Res Date: 2008-06 Impact factor: 4.200
Authors: Suzanne M D'Addio; John Gar Yan Chan; Philip Chi Lip Kwok; Bryan R Benson; Robert K Prud'homme; Hak-Kim Chan Journal: Pharm Res Date: 2013-07-27 Impact factor: 4.200
Authors: Paul A Burke; Lisa A Klumb; John D Herberger; Xichdao C Nguyen; Roy A Harrell; Monica Zordich Journal: Pharm Res Date: 2004-03 Impact factor: 4.200